A Single-center, Randomized, Double-blind, Placebo-controlled, Three-way Crossover Phase I Study to Investigate the Effect on the QTc Interval of a Single Dose of AZD6094 (600 mg) Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positive Control, in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Savolitinib (Primary) ; Moxifloxacin
- Indications Adenocarcinoma; Gastric cancer; Lung cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 29 Sep 2017 Planned End Date changed from 27 Dec 2017 to 9 Jan 2018.
- 29 Sep 2017 Planned primary completion date changed from 27 Dec 2017 to 9 Jan 2018.
- 29 Sep 2017 Status changed from not yet recruiting to recruiting.